[Journal logo]

Volume 65 
Part 3 
Page o542  
March 2009  

Received 20 January 2009
Accepted 9 February 2009
Online 18 February 2009

Key indicators
Single-crystal X-ray study
T = 110 K
Mean [sigma](C-C) = 0.004 Å
R = 0.052
wR = 0.112
Data-to-parameter ratio = 17.9
Details
Open access

1,2-Bis(di-2-pyridylphosphinoyl)ethane

aChemistry, School of Biomedical, Biomolecular and Chemical Sciences, The University of Western Australia, 35 Stirling Highway, Crawley, Perth 6009, Western Australia, Australia
Correspondence e-mail: brian.skelton@uwa.edu.au

The crystal structure of the title compound, C22H20N4O2P2, consists of two independent half-molecules, both of which lie on crystallographic inversion centres. There are no significant differences between the two molecules.

Related literature

For the antitumour properties of metal complexes of bidentate tertiary phosphine ligands with pyridyl substituents, see: McKeage et al. (2000[McKeage, M. J., Berners-Price, S. J., Galettis, P., Bowen, R. J., Brouwer, W., Ding, L., Zhuang, L. & Baguley, B. C. (2000). Cancer Chemother. Pharmacol. 46, 343-350.]); Barnard & Berners-Price (2007[Barnard, P. J. & Berners-Price, S. J. (2007). Coord. Chem. Rev. 251, 1889-1902.]); Liu et al. (2008[Liu, J. J., Galettis, P., Farr, A., Maharaj, L., Samarasinha, H., McGechan, A. C., Baguley, B. C., Bowen, R. J., Berners-Price, S. J. & McKeage, M. J. (2008). J. Inorg. Biochem. 102, 303-310.]). The crystal structure of the parent 1,2-bis(di-2-pyridylphosphino)ethane molecule has been determined (Jones et al., 1999[Jones, N. D., MacFarlane, K. S., Smith, M. B., Schutte, R. P., Rettig, S. J. & James, B. R. (1999). Inorg. Chem. 38, 3956-3966.]). The structure of 1,2-bis(di-phenylphosphino)ethane dioxide (Calcagno et al., 2000[Calcagno, P., Kariuki, B. M., Kitchin, S. J., Robinson, J. M. A., Philp, D. & Harris, K. D. M. (2000). Chem. Eur. J. 6, 2338-2349.]) is similar, with the two halves of the molecule related by a pseudo-inversion centre, but this is not isomorphous with the title compound.

[Scheme 1]

Experimental

Crystal data
  • C22H20N4O2P2

  • Mr = 434.36

  • Triclinic, [P \overline 1]

  • a = 8.3760 (6) Å

  • b = 8.8496 (8) Å

  • c = 16.2332 (11) Å

  • [alpha] = 105.627 (7)°

  • [beta] = 92.429 (5)°

  • [gamma] = 112.559 (7)°

  • V = 1055.67 (16) Å3

  • Z = 2

  • Mo K[alpha] radiation

  • [mu] = 0.23 mm-1

  • T = 110 K

  • 0.22 × 0.10 × 0.06 mm

Data collection
  • Oxford Diffraction Gemini diffractometer

  • Absorption correction: Gaussian (CrysAlis RED; Oxford Diffraction, 2008[Oxford Diffraction (2008). CrysAlis CCD and CrysAlis RED. Oxford Diffraction Ltd, Abingdon, Oxfordshire, England.]) Tmin = 0.968, Tmax = 0.988

  • 10983 measured reflections

  • 4842 independent reflections

  • 2698 reflections with I > 2[sigma](I)

  • Rint = 0.059

Refinement
  • R[F2 > 2[sigma](F2)] = 0.052

  • wR(F2) = 0.112

  • S = 0.86

  • 4842 reflections

  • 271 parameters

  • H-atom parameters constrained

  • [Delta][rho]max = 0.43 e Å-3

  • [Delta][rho]min = -0.34 e Å-3

Data collection: CrysAlis CCD (Oxford Diffraction, 2008[Oxford Diffraction (2008). CrysAlis CCD and CrysAlis RED. Oxford Diffraction Ltd, Abingdon, Oxfordshire, England.]); cell refinement: CrysAlis RED (Oxford Diffraction, 2008[Oxford Diffraction (2008). CrysAlis CCD and CrysAlis RED. Oxford Diffraction Ltd, Abingdon, Oxfordshire, England.]); data reduction: CrysAlis RED; program(s) used to solve structure: SIR92 (Altomare et al., 1994[Altomare, A., Cascarano, G., Giacovazzo, C., Guagliardi, A., Burla, M. C., Polidori, G. & Camalli, M. (1994). J. Appl. Cryst. 27, 435.]); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008[Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.]); molecular graphics: ORTEPII (Johnson, 1976[Johnson, C. K. (1976). ORTEPII. Report ORNL-5138. Oak Ridge National Laboratory, Tennessee, USA.]); software used to prepare material for publication: publCIF (Westrip, 2009[Westrip, S. P. (2009). publCIF. In preparation.]).


Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: FJ2193 ).


Acknowledgements

The authors thank the Australian Research Council for financial assistance.

References

Altomare, A., Cascarano, G., Giacovazzo, C., Guagliardi, A., Burla, M. C., Polidori, G. & Camalli, M. (1994). J. Appl. Cryst. 27, 435.  [CrossRef] [details]
Barnard, P. J. & Berners-Price, S. J. (2007). Coord. Chem. Rev. 251, 1889-1902.  [ISI] [CrossRef] [ChemPort]
Calcagno, P., Kariuki, B. M., Kitchin, S. J., Robinson, J. M. A., Philp, D. & Harris, K. D. M. (2000). Chem. Eur. J. 6, 2338-2349.  [CrossRef] [PubMed] [ChemPort]
Johnson, C. K. (1976). ORTEPII. Report ORNL-5138. Oak Ridge National Laboratory, Tennessee, USA.
Jones, N. D., MacFarlane, K. S., Smith, M. B., Schutte, R. P., Rettig, S. J. & James, B. R. (1999). Inorg. Chem. 38, 3956-3966.  [ISI] [CrossRef] [ChemPort]
Liu, J. J., Galettis, P., Farr, A., Maharaj, L., Samarasinha, H., McGechan, A. C., Baguley, B. C., Bowen, R. J., Berners-Price, S. J. & McKeage, M. J. (2008). J. Inorg. Biochem. 102, 303-310.  [ISI] [CrossRef] [PubMed] [ChemPort]
McKeage, M. J., Berners-Price, S. J., Galettis, P., Bowen, R. J., Brouwer, W., Ding, L., Zhuang, L. & Baguley, B. C. (2000). Cancer Chemother. Pharmacol. 46, 343-350.  [ISI] [CrossRef] [PubMed] [ChemPort]
Oxford Diffraction (2008). CrysAlis CCD and CrysAlis RED. Oxford Diffraction Ltd, Abingdon, Oxfordshire, England.
Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.  [CrossRef] [details]
Westrip, S. P. (2009). publCIF. In preparation.


Acta Cryst (2009). E65, o542  [ doi:10.1107/S1600536809004590 ]

This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.